Disease · MONDO_0100347
carcinoid syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. carcinoid syndrome. Diseases, record MONDO_0100347. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100347
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TELOTRISTAT ETHYL | CHEMBL2105695 | Small molecule | Approval | TTD | 6 | 5 | 5 | Drugs and targets |
| LANREOTIDE ACETATE | CHEMBL1201184 | Protein | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| LANREOTIDE | CHEMBL1201185 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TELOTRISTAT | CHEMBL2103855 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PALTUSOTINE | CHEMBL5267842 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
| SUROTOMYCIN | CHEMBL2375161 | Protein | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| OCTREOTIDE | CHEMBL1680 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ONZIGOLIDE | CHEMBL4650342 | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets | |
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PANITUMUMAB | CHEMBL1201827 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SSTR2 | Somatostatin receptor | 6 | Somatostatin receptor 2 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 5 | Somatostatin receptor 5 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6755 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6751 | Drugs and targets |
| SSTR3 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6753 | Drugs and targets |
| SSTR4 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6754 | Drugs and targets |
| TPH1 | Tryptophan 5-hydroxylase | 2 | Tryptophan 5-hydroxylase inhibitor | Approval | https://conductscience.org/library/genes/7166 | Drugs and targets |
| TPH2 | Tryptophan 5-hydroxylase | 2 | Tryptophan 5-hydroxylase inhibitor | Approval | https://conductscience.org/library/genes/121278 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 1 | Dopamine D2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 antagonist | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
Trials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03223428 | Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO | 223 | 2024-07-15 | Carcinoid Syndrome | TELOTRISTAT ETHYL | Its record names the disease | ClinicalTrials.gov | |
| NCT01677910 | TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) | Phase 3 | 135 | 2017-09-18 | Carcinoid Syndrome | TELOTRISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00774930 | An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome | Phase 3 | 115 | 2016-02-09 | Carcinoid Syndrome | LANREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04810091 | Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor | Phase 3 | 79 | 2026-02-05 | Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm | TELOTRISTAT ETHYL | Its record names the disease | ClinicalTrials.gov |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | Phase 2 | 36 | 2025-10-31 | Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas | PALTUSOTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00853047 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy | Phase 2 | 23 | 2018-12-26 | Carcinoid Syndrome | OCTREOTIDE, TELOTRISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01104415 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome | Phase 2 | 15 | 2018-04-06 | Carcinoid Syndrome | TELOTRISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01018953 | Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome | Phase 2 | 8 | 2015-09-07 | Carcinoid Syndrome | ONZIGOLIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01886287 | P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome | Phase 2 | 2 | 2015-01-12 | Neuroendocrine Carcinoma | OCTREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | 141 | Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor | PALTUSOTINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Placebo + SSA vs Xermelo + SSA: deaths from any cause | 1 of 35 | 0 of 32 | 67 | NCT04810091 | Trial comparisons |
| Placebo + SSA vs Xermelo + SSA: serious adverse events | 3 of 35 | 4 of 32 | 67 | NCT04810091 | Trial comparisons |
| 40 mg Paltusotine vs 80 mg Paltusotine: deaths from any cause | 0 of 18 | 1 of 18 | 36 | NCT05361668 | Trial comparisons |
| 40 mg Paltusotine vs 80 mg Paltusotine: serious adverse events | 2 of 18 | 2 of 18 | 36 | NCT05361668 | Trial comparisons |
| Telotristat Etiprate- Core Phase vs Telotristat Etiprate- Extension Period: deaths from any cause | 0 of 15 | 1 of 11 | 26 | NCT01104415 | Trial comparisons |
| Telotristat Etiprate- Core Phase vs Telotristat Etiprate- Extension Period: serious adverse events | 3 of 15 | 7 of 11 | 26 | NCT01104415 | Trial comparisons |
| Telotristat Etiprate- Core Phase vs Telotristat Etiprate- Extension Period: Number of Participants With an Improvement in Global Assessment of Symptoms Associated With Carcinoid Syndrome | 10 of 13 | 4 of 7 | 20 | NCT01104415 | Trial comparisons |
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 36262750 | RESULT | 1 | PubMed |
| 27214300 | RESULT | 1 | PubMed |
| 34598813 | DERIVED | 1 | PubMed |
| 32157590 | DERIVED | 1 | PubMed |
| 32146619 | DERIVED | 1 | PubMed |
| 31754316 | DERIVED | 1 | PubMed |
| 31655936 | DERIVED | 1 | PubMed |
| 30477789 | DERIVED | 1 | PubMed |
| 29724499 | DERIVED | 1 | PubMed |
| 27041406 | DERIVED | 1 | PubMed |
1 to 10 of 12
See all 12 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100347
GET https://conductscience.org/api/diseases/v1/MONDO_0100347/drugs